Lifecore director granted 25,907 RSUs

Lifecore Biomedical director Katrina Houde received an equity grant in the form of restricted stock units.

Rhea-AI Filing Summary

Lifecore Biomedical director Katrina Houde received an equity grant in the form of restricted stock units. She was awarded 25,907 shares of Common Stock on June 4, 2026 as a grant or award, at a stated price of $0.00 per share, indicating compensation rather than an open-market purchase.

After this grant, Houde directly holds 135,319 shares of Lifecore Biomedical common stock. According to the footnotes, the restricted stock units convert into common stock on a 1-for-1 basis and vest on the earlier of June 4, 2027 or the date of the company’s 2027 annual stockholder meeting, provided that meeting occurs at least 50 weeks after the grant date.

Insider Trade Summary

Grant/Award: 25,907 shares

Grant/Award 1 txn

Insider HOUDE LOVAS KATRINA

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	25,907	$0.00	$0.00

Holdings After Transaction: Common Stock — 135,319 shares (Direct)

Footnotes (2)

1. F1. The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
2. F2. Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Key Figures

RSU grant size: 25,907 shares Grant price: $0.00 per share Shares held after grant: 135,319 shares +2 more

5 metrics

RSU grant size 25,907 shares Restricted stock units granted on June 4, 2026

Grant price $0.00 per share Stated transaction price for RSU award

Shares held after grant 135,319 shares Director’s direct common stock holdings post-transaction

Vesting date June 4, 2027 Latest vesting date for the RSUs, subject to earlier annual meeting

Conversion ratio 1-for-1 Each restricted stock unit converts into one common share

Key Terms

restricted stock units, vests, grant, award, or other acquisition, Common Stock

4 terms

restricted stock units financial

"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vests financial

"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027..."

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Lifecore Biomedical (LFCR) report for Katrina Houde?

Lifecore Biomedical reported that director Katrina Houde received a grant of 25,907 shares of common stock as restricted stock units on June 4, 2026. The grant was a compensation award at a stated price of $0.00 per share, not an open-market purchase.

How many Lifecore Biomedical (LFCR) shares does Katrina Houde hold after this Form 4?

Following the reported grant, Katrina Houde directly holds 135,319 shares of Lifecore Biomedical common stock. This figure reflects her position after receiving 25,907 restricted stock units that convert into common stock on a one-for-one basis once vested.

What are the vesting terms of Katrina Houde’s restricted stock units at Lifecore Biomedical (LFCR)?

The restricted stock units vest on the earlier of June 4, 2027, or the date of Lifecore Biomedical’s 2027 annual stockholder meeting. The meeting date must occur at least 50 weeks after June 4, 2026 for this alternative vesting condition to apply.

Do Katrina Houde’s restricted stock units at Lifecore Biomedical (LFCR) convert directly into common stock?

Yes. The footnotes state that the restricted stock units convert into Lifecore Biomedical common stock on a 1-for-1 basis. This means each vested unit becomes one share of common stock once the vesting conditions are satisfied under the grant terms.

Was Katrina Houde’s Lifecore Biomedical (LFCR) grant an open-market stock purchase?

No. The transaction is coded as a grant, award, or other acquisition with a transaction price of $0.00 per share. This indicates a compensation-related equity award rather than an open-market purchase where cash is paid to acquire existing shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HOUDE LOVAS KATRINA

(Last) (First) (Middle)

C/O LIFECORE BIOMEDICAL, INC.

3515 LYMAN BLVD.

(Street)

CHASKA MINNESOTA 55318

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIFECORE BIOMEDICAL, INC. \DE\ [ LFCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		A		25,907	A	(1)(2)	135,319	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

2. Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Remarks:

	/s/ Courtney Schuler, Attorney-In-Fact for Katrina Houde Lovas	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)